{"id":"W4281685079","doi":"10.1200/jco.2022.40.16_suppl.tps5617","title":"ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bevacizumab; Ovarian cancer; Pembrolizumab; Internal medicine; Paclitaxel; Oncology; Chemotherapy; Placebo; Response Evaluation Criteria in Solid Tumors; Surgery; Phases of clinical research; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00253525,0.002182576,0.002680265,0.0006863326,0.0004928786,0.001173244,0.001549728,0.002282328,0.01048173],"category_scores_gemma":[0.00166092,0.001029497,0.002162667,0.0006139164,0.001440336,0.001469545,0.0005248737,0.004196695,0.001810576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009790517,"about_ca_system_score_gemma":0.001861493,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001133502,"about_ca_topic_score_gemma":0.002869646,"domain_scores_codex":[0.9993715,0.0003045482,0.00004032622,0.0001249989,0.00005933651,0.00009943725],"domain_scores_gemma":[0.9990978,0.0001847622,0.0002958301,0.000070492,0.00004707684,0.000304058],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9697104,0.01278657,0.0003676246,0.000785868,0.0005952657,0.00003153167,0.00004388469,0.0002151651,0.003598927,0.00010776,0.0009782822,0.01077873],"study_design_scores_gemma":[0.9551378,0.04304831,0.0006350524,0.00002422726,0.0001829842,0.00002714119,0.00001099605,0.0001649093,0.0002887324,0.00008007286,0.0003897891,0.000009975844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9675844,0.007157447,0.00145625,0.0008991716,0.0009549422,0.01470753,0.00299711,0.0004818538,0.003761411],"genre_scores_gemma":[0.9698335,0.003842916,0.003279302,0.001950262,0.0004949356,0.01265875,0.002336656,0.00006414261,0.005539551],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01048173,"threshold_uncertainty_score":0.03506494,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2175992567528424,"score_gpt":0.5038330728052243,"score_spread":0.2862338160523819,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}